China Resources Pharmaceutical Group (01093.HK) released its interim results, with a net profit attributable to shareholders of 2.548 billion yuan, a decrease of 15.64% year-on-year.

Zhito Finance APP news, China Pharma Group (01093.HK) released its mid-year performance in 2025. The group's total revenue for the period was 13.273 billion yuan, a decrease of 18.5% year-on-year. The attributable profit to owners of the company was 2.548 billion yuan, a decrease of 15.64% year-on-year. The basic earnings per share were 22.29 cents. It is proposed to distribute an interim dividend of 14 Hong Kong cents per share.